FALLS CHURCH, Va.--(BUSINESS WIRE)--Retension Pharmaceuticals, Inc. is pleased to announce the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives..

弗吉尼亚州福尔斯彻奇市（商业新闻短讯）--Retension Pharmaceuticals，Inc.很高兴宣布其1040万美元的A系列融资回合成功结束，以启动一项功能强大且受控的2期临床研究，该研究针对两种或两种以上抗高血压药不受控制的高血压患者。

Retension Pharmaceuticals is a clinical-stage therapeutic development company focused on developing innovative treatments for hypertension and cardiovascular disease. The company's lead drug candidate, RTN-001, a second generation PDE5 inhibitor, was designed to target the tissues of the higher vasculature by the company’s CSO and Co-Founder, Dr.

Rettension Pharmaceuticals是一家临床阶段治疗开发公司，专注于开发高血压和心血管疾病的创新治疗方法。该公司的主要候选药物RTN-001是第二代PDE5抑制剂，由该公司的CSO和联合创始人Dr。

Paul Sweetnam, overcoming the limitations of first generation PDE5 inhibitors in the hypertension space. According to the WHO, it is estimated that hypertension affects 1.28 billion adults worldwide, of whom only 21% have their hypertension fully under control. In prior clinical trials, RTN-001 has been studied in over 265 human subjects, including two Phase 2 studies in patients with uncontrolled hypertension.

Paul Sweetnam，克服了第一代PDE5抑制剂在高血压领域的局限性。据世界卫生组织估计，全世界有12.8亿成年人患有高血压，其中只有21%的人的高血压得到了完全控制。在之前的临床试验中，RTN-001已在265多名人类受试者中进行了研究，包括两项针对未控制高血压患者的2期研究。

In these studies, RTN-001 was shown to be well tolerated and demonstrated clinically significant blood pressure lowering effects..

在这些研究中，RTN-001被证明具有良好的耐受性，并显示出临床上显着的降血压作用。

“With a strong existing clinical data set, an established mechanism of action and FDA’s guidance document for the streamlined development of new antihypertension agents, Retension Pharmaceuticals is positioned to rapidly and efficiently develop RTN-001 for success in a population with significant unmet medical needs,” said Eric Keller, CEO and Co-Founder.

首席执行官兼联合创始人埃里克·凯勒（EricKeller）表示：“Retenting Pharmaceuticals拥有强大的现有临床数据集、既定的行动机制和FDA关于简化新型抗高血压药物开发的指导文件，能够快速有效地开发RTN-001，以在医疗需求严重未得到满足的人群中取得成功。”

“We are thrilled with the close of our first external financing round and incredibly appreciative of the support we have received from Collage Venture Partners and our new investors, many of whom have a deep understanding of our disease areas and the critical need for new and efficacious hypertension treatments.”.

“我们对第一轮外部融资的结束感到兴奋，并非常感谢我们从大学风险投资伙伴和新投资者那里获得的支持，他们中的许多人对我们的疾病领域以及对新的有效高血压治疗的迫切需求有着深刻的了解。”

“The loss of nitric oxide production contributes importantly to hypertension,” said Dr. Jonathan Stamler, Distinguished University Professor and the Robert S. and Sylvia K. Reitman Family Foundation, Distinguished Chair in Cardiovascular Innovation, University Hospitals and CWRU, Cleveland. “Inhibition of PDE5 is a long-desired mechanism for enhancing NO-based signaling for the treatment of hypertension, and I am very pleased to see Retension Pharmaceuticals progress this important new therapeutic option for patients with uncontrolled and resistant hypertension.”.

“一氧化氮产生的减少对高血压有重要贡献，”著名大学教授乔纳森·斯坦勒博士说，罗伯特·S·和西尔维亚·K·雷特曼家族基金会是克利夫兰大学医院心血管创新杰出主席和CWRU杰出主席。“抑制PDE5是增强高血压治疗中基于NO的信号传导的长期理想机制，我很高兴看到Retension Pharmaceuticals为不受控制和耐药性高血压患者取得了这一重要的新治疗选择。”

Commenting on the clinical development program for RTN-001, Chief Medical Officer Dr. Bill Sasiela noted: “As someone new to this program, I have examined the prior clinical study data and was impressed by the robustness of the efficacy effects in patients already on up to four antihypertensives. With an established mechanism with well-studied safety and tolerability and demonstrated ability to reduce blood pressure on top of standard therapy, RTN-001 is a significantly de-risked experimental therapeutic agent that has the potential to be a paradigm-shifting treatment.”.

首席医疗官Bill Sasiela博士在评论RTN-001的临床开发计划时指出：“作为该计划的新手，我已经检查了之前的临床研究数据，并且对已经对多达四种抗高血压药物的患者的疗效效果的稳健性印象深刻。RTN-001具有经过充分研究的安全性和耐受性的既定机制，并且证明了在标准治疗的基础上降低血压的能力，是一种显着降低风险的实验治疗剂，有可能成为一种范式转换治疗。”

The proceeds from the financing round will be used to fund an efficacy study for RTN-001 and support the company's ongoing development efforts.

融资回合的收益将用于资助RTN-001的功效研究，并支持公司正在进行的开发工作。

About Hypertension

关于高血压

Having high blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the U.S. In 2023, more than 680,000 deaths in the U.S. included hypertension as a primary or contributing cause. High blood pressure and related health issues resulted in an average annual economic burden of about $131 billion each year in the U.S., averaged over 12 years from 2003 to 2014..

高血压（或高血压）会增加心脏病、心脏病发作和中风的风险，这是美国的主要死亡原因。2023年，美国超过680000人死亡，其中高血压是主要或促成原因。高血压和相关健康问题导致美国每年平均经济负担约为1310亿美元，从2003年到2014年平均为12年。

About Retension Pharmaceuticals

关于Retention Pharmaceuticals

Retension Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing RTN-001 as a therapy for patients with hypertension. RTN-001 is a unique second generation inhibitor of PDE5 that, unlike earlier PDE5 inhibitors for erectile dysfunction, preferentially distributes to cardiovascular tissues.

Rettension Pharmaceuticals，Inc.是一家临床阶段生物技术公司，开发RTN-001作为高血压患者的治疗药物。RTN-001是一种独特的第二代PDE5抑制剂，与早期用于勃起功能障碍的PDE5抑制剂不同，它优先分布于心血管组织。

The compound is a potent and selective modulator of cGMP and has been studied in multiple clinical trials including over 265 subjects. It was well-tolerated and has demonstrated the promise of efficacy in early studies of patients with uncontrolled hypertension with blood pressure lowering on par with most established and clinical stage antihypertensives and reductions in central blood pressure..

该化合物是cGMP的有效和选择性调节剂，已在包括265多名受试者在内的多项临床试验中进行了研究。它具有良好的耐受性，并且在早期研究中证明了对不受控制的高血压患者的疗效，其血压降低与大多数已建立和临床阶段的抗高血压药和中枢血压降低相当。

Retension Pharmaceuticals is preparing to evaluate RTN-001 in an expanded Phase 2 program focusing on resistant and uncontrolled hypertension. RTN-001 is being developed under an exclusive world-wide license from Sanofi S.A.

Rettension Pharmaceuticals正准备在一个扩展的2期计划中评估RTN-001，该计划侧重于耐药性和不受控制的高血压。RTN-001是在赛诺菲公司的全球独家许可下开发的。

For more information please see www.retensionpharmaceuticals.com

有关更多信息，请访问www.retensionpharmaticals.com